Cargando…

Reimbursement decision-making system in Poland systematically compared to other countries

Introduction: Our objective was to analyze and compare systematically and structurally reimbursement systems in Poland and other countries. Methods: The systems were selected based on recommendations issued by the Polish Agency for Health Technology Assessment and Tariffication (AHTAPol), which expl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mela, Aneta, Rdzanek, Elżbieta, Jaroszyński, Janusz, Furtak-Niczyporuk, Marzena, Jabłoński, Mirosław, Niewada, Maciej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611478/ https://www.ncbi.nlm.nih.gov/pubmed/37900165 http://dx.doi.org/10.3389/fphar.2023.1153680

Ejemplares similares

Economic Costs of Cardiovascular Diseases in Poland Estimates for 2015–2017 Years
por: Mela, Aneta, et al.
Publicado: (2020)

Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years
por: Mela, Aneta, et al.
Publicado: (2020)

Brain Functional Reserve in the Context of Neuroplasticity after Stroke
por: Dąbrowski, Jan, et al.
Publicado: (2019)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017)

Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis
por: Czech, Marcin, et al.
Publicado: (2015)

Decreased Cerebrospinal Fluid Orexin-A (Hypocretin-1) Concentrations in Patients after Generalized Convulsive Status Epilepticus
por: Samzadeh, Mojdeh, et al.
Publicado: (2020)

Decision-making criteria for medicine reimbursement in Slovenia: an expert panel discussion
por: Detiček, Andreja, et al.
Publicado: (2018)

Drug pricing and reimbursement information management: processes and decision making in the global economy
por: Tsourougiannis, Dimitrios
Publicado: (2017)

How Should the Value Attributes of Novel Antibiotics Be Considered in Reimbursement Decision Making?
por: Morton, Alec, et al.
Publicado: (2019)

Role of centralized review processes for making reimbursement decisions on new health technologies in Europe
por: Stafinski, Tania, et al.
Publicado: (2011)

“Budget Impact Analyses”: A Practical Policy Making Tool for Drug Reimbursement Decisions
por: Jamshidi, Hamid Reza, et al.
Publicado: (2014)

The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?
por: Lux, Michael Patrick, et al.
Publicado: (2021)

A Systematic Review of the Cyclooxygenase-2 (COX-2) Expression in Rectal Cancer Patients Treated with Preoperative Radiotherapy or Radiochemotherapy
por: Berbecka, Monika, et al.
Publicado: (2021)

Recommendations for the Implementation of Hospital Based HTA in Poland: Lessons Learned From International Experience
por: Gałązka-Sobotka, Małgorzata, et al.
Publicado: (2021)

Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement
por: Tse, Vicki C, et al.
Publicado: (2011)

Informed decision‐making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments
por: Weir, Christopher J., et al.
Publicado: (2022)

A Process for Evaluating Quality Decision-Making Practices During the Development, Review and Reimbursement of Medicines
por: Bujar, Magdalena, et al.
Publicado: (2020)

The cost-effectiveness of food consistency modification with xanthan gum-based Nutilis Clear® in patients with post-stroke dysphagia in Poland
por: Pelczarska, Aleksandra, et al.
Publicado: (2020)

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab
por: Niewada, Maciej, et al.
Publicado: (2023)

Pre-reimbursement: early assessment for coverage decisions
por: Grössmann, Nicole, et al.
Publicado: (2019)

Colorectal Cancer—The Worst Enemy Is the One We Do Not Know
por: Furtak-Niczyporuk, Marzena, et al.
Publicado: (2023)

‘Other’ Posts in ‘Other’ Places: Poland through a Postcolonial Lens?
por: Mayblin, Lucy, et al.
Publicado: (2016)

Reimbursement categories as a way of allocating measures and monitoring expenditures on medicines
por: Lipińska, Aneta, et al.
Publicado: (2015)

Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey
por: Polisena, Julie, et al.
Publicado: (2017)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Tritrichomonas Foetus: A Study of Prevalence in Animal Hosts in Poland
por: Dąbrowska, Joanna, et al.
Publicado: (2020)

First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland
por: Nowicki, Michał, et al.
Publicado: (2021)

Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe
por: Golicki, Dominik, et al.
Publicado: (2019)

Implantable Cardioverter-Defibrillators in Poland Compared with other European Countries from the Patient’s Perspective: Insights from the EHRA Patient Survey
por: Januszkiewicz, Łukasz, et al.
Publicado: (2023)

Occurrence of West Nile Virus Antibodies in Wild Birds, Horses, and Humans in Poland
por: Niczyporuk, Jowita Samanta, et al.
Publicado: (2015)

Comparative Analysis of the Incidence of Selected Sexually Transmitted Bacterial Infections in Poland in 2010–2015: A Retrospective Cohort Study
por: Orzechowska, Magda, et al.
Publicado: (2022)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

The impact of country reimbursement programmes on living kidney donations
por: Siddique, Abu Bakkar, et al.
Publicado: (2020)

Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions
por: Roszkowski, Krzysztof, et al.
Publicado: (2016)

Using multicriteria decision analysis during drug development to predict reimbursement decisions
por: Williams, Paul, et al.
Publicado: (2014)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
por: Badora, Karolina, et al.
Publicado: (2017)

Discontinuation of reimbursement of benzodiazepines in the Netherlands: does it make a difference?
por: Kollen, Boudewijn J, et al.
Publicado: (2012)

Health Economic Data in Reimbursement of New Medical Technologies: Importance of the Socio-Economic Burden as a Decision-Making Criterion
por: Iskrov, Georgi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vmkq0oeuoc78i306jtanobuh9i